Wall Street Zen Upgrades Whitehawk Therapeutics (NASDAQ:WHWK) to Hold

Whitehawk Therapeutics (NASDAQ:WHWK) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

WHWK has been the topic of several other research reports. Oppenheimer initiated coverage on Whitehawk Therapeutics in a research note on Thursday, February 5th. They set an “outperform” rating and a $6.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Monday, December 29th. Finally, JonesTrading started coverage on shares of Whitehawk Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Whitehawk Therapeutics has a consensus rating of “Hold” and an average price target of $6.50.

Whitehawk Therapeutics Stock Performance

Shares of Whitehawk Therapeutics stock opened at $3.59 on Friday. Whitehawk Therapeutics has a fifty-two week low of $1.39 and a fifty-two week high of $4.48. The company has a market capitalization of $169.45 million, a P/E ratio of 7.64 and a beta of 0.51. The company has a fifty day moving average of $3.14 and a 200 day moving average of $2.54.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of hedge funds have recently made changes to their positions in WHWK. Avoro Capital Advisors LLC bought a new position in Whitehawk Therapeutics during the third quarter valued at approximately $5,414,000. Suvretta Capital Management LLC bought a new stake in Whitehawk Therapeutics in the 3rd quarter worth approximately $7,030,000. Ally Bridge Group NY LLC bought a new stake in Whitehawk Therapeutics in the 3rd quarter worth approximately $1,554,000. Peapod Lane Capital LLC purchased a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $577,000. Finally, ABG Innovation Capital Partners III GP Ltd purchased a new stake in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $51,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.